{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:40:09Z","timestamp":1792791609582,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Including all relevant costs and effects in economic evaluations can be challenging, especially when spillovers in other individuals or sectors are likely. Previous literature has highlighted that the combination of relevant spillovers is evaluation and context specific. This emphasises the importance of identifying (the evidence on) relevant spillovers systematically. Spillovers are defined here as \u201call impacts from an intervention on all parties or entities other than the users of the intervention under evaluation\u201d. In this study, we evaluate the feasibility of applying the recently introduced Expanded Impact Inventory to identify (evidence on) potentially relevant spillovers. If feasible, this approach can help to determine the analytical scope of health economic evaluations and to identify the available knowledge (gaps). As an illustration, we use two case studies: vaccination against acute respiratory diseases and herpes zoster. Using the inventory to guide a rapid review of economic studies in these disease areas, we found that commonly considered spillovers are patient healthcare and productivity costs\u2013in so far these are borne by others than the patient\u2013, as well as caregiving time costs. Spillover impacts on health, broader quality of life, and productivity of others, especially caregivers, were often highlighted as important, though evidence remains limited. This application demonstrates that using the Expanded Impact Inventory to identify (evidence on) potentially relevant spillovers and delineate the scope of economic evaluations is feasible. Using this framework across various interventions and disease areas can promote the systematic consideration of broader impacts in economic evaluations, strengthening the evidence base for spillovers and improving the comprehensiveness and comparability of economic evaluations.<\/jats:p>","DOI":"10.1007\/s10198-026-02000-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:32:00Z","timestamp":1792729920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring spillovers of vaccines: A practical application of the Expanded Impact Inventory"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-5687","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Mendoza-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job","family":"van Exel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner B. F.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"1","key":"2000_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","volume":"21","author":"H Al-Janabi","year":"2012","unstructured":"Al-Janabi, H., T. N. Flynn, and J. Coast. 2012. Development of a self-report measure of capability wellbeing for adults: The ICECAP-A. Quality of Life Research 21 (1): 167\u2013176. https:\/\/doi.org\/10.1007\/s11136-011-9927-2.","journal-title":"Quality of Life Research"},{"issue":"12","key":"2000_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi, H., J. Van Exel, W. Brouwer, et al. 2016a. Measuring health spillovers for economic evaluation: A case study in meningitis. Health Economics 25 (12): 1529\u20131544. https:\/\/doi.org\/10.1002\/hec.3259.","journal-title":"Health Economics"},{"issue":"2","key":"2000_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0272989X15605094","volume":"36","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi, H., J. van Exel, W. Brouwer, and J. Coast. 2016b. A framework for including family health spillovers in economic evaluation. Medical Decision Making 36 (2): 176\u2013186. https:\/\/doi.org\/10.1177\/0272989X15605094.","journal-title":"Medical Decision Making"},{"issue":"664","key":"2000_CR4","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/ej\/ueae051","volume":"134","author":"EG Aslim","year":"2024","unstructured":"Aslim, E. G., W. Fu, C. L. Liu, and E. Tekin. 2024. Vaccination policy, delayed care and health expenditures. Economic Journal 134 (664): 3096\u20133136. https:\/\/doi.org\/10.1093\/ej\/ueae051.","journal-title":"Economic Journal"},{"key":"2000_CR5","unstructured":"Banhawi, H. E. l., S. Chowdhury, M. Neri, et al. 2024. The socio-economic value of adult immunisation programmes."},{"issue":"34","key":"2000_CR6","doi-asserted-by":"publisher","first-page":"12313","DOI":"10.1073\/pnas.1400475111","volume":"111","author":"T B\u00e4rnighausen","year":"2014","unstructured":"B\u00e4rnighausen, T., D. E. Bloom, E. T. Cafiero-Fonseca, and J. C. O\u2019Brien. 2014. Valuing vaccination. Proceedings of the National Academy of Sciences of the United States of America 111 (34): 12313\u201312319. https:\/\/doi.org\/10.1073\/pnas.1400475111.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"30","key":"2000_CR7","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1016\/j.vaccine.2022.04.050","volume":"40","author":"E Beck","year":"2022","unstructured":"Beck, E., E. Biundo, N. Devlin, et al. 2022. Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine. 40 (30): 4008\u20134016. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.050.","journal-title":"Vaccine."},{"issue":"1","key":"2000_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","volume":"20","author":"E Bell","year":"2022","unstructured":"Bell, E., M. Neri, and L. Steuten. 2022. Towards a broader assessment of value in vaccines: The BRAVE way forward. Applied Health Economics and Health Policy 20 (1): 105\u2013117. https:\/\/doi.org\/10.1007\/s40258-021-00683-z.","journal-title":"Applied Health Economics and Health Policy"},{"issue":"3","key":"2000_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1017\/S026646231900028X","volume":"35","author":"A Bhadhuri","year":"2019","unstructured":"Bhadhuri, A., H. Al-Janabi, S. Jowett, and K. Jolly. 2019. Incorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD. International Journal of Technology Assessment in Health Care 35 (3): 212\u2013220. https:\/\/doi.org\/10.1017\/S026646231900028X.","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"2000_CR10","unstructured":"Bloom. D., D. Canning, M. Weston. 2005. The value of vaccination. World Economics. 6 (3): 15\u201339. https:\/\/econpapers.repec.org\/RePEc:wej:wldecn:213."},{"issue":"6","key":"2000_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270086","volume":"17","author":"L Castillo-Rodr\u00edguez","year":"2022","unstructured":"Castillo-Rodr\u00edguez, L., D. Malo-S\u00e1nchez, D. D\u00edaz-Jim\u00e9nez, I. Garc\u00eda-Vel\u00e1squez, P. Pulido, and C. Casta\u00f1eda-Orjuela. 2022. Economic costs of severe seasonal influenza in Colombia, 2017-2019: A multi-center analysis. PLoS ONE 17 (6) : e0270086. https:\/\/doi.org\/10.1371\/journal.pone.0270086.","journal-title":"PLoS ONE"},{"issue":"2","key":"2000_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40273-018-0735-1","volume":"37","author":"ET Chiyaka","year":"2019","unstructured":"Chiyaka, E. T., V. T. Nghiem, L. Zhang, A. Deshpande, P. D. Mullen, and P. Le. 2019. Cost-effectiveness of herpes zoster vaccination: A systematic review. PharmacoEconomics 37 (2): 169\u2013200. https:\/\/doi.org\/10.1007\/s40273-018-0735-1.","journal-title":"PharmacoEconomics"},{"key":"2000_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.116027","volume":"329","author":"RL Coley","year":"2023","unstructured":"Coley, R. L., N. Carey, C. F. Baum, and S. S. Hawkins. 2023. COVID-19 vaccinations and mental health among U.S. adults: Individual and spillover effects. Social Science & Medicine 329 : 116027. https:\/\/doi.org\/10.1016\/j.socscimed.2023.116027.","journal-title":"Social Science & Medicine"},{"issue":"Suppl 1","key":"2000_CR14","doi-asserted-by":"publisher","first-page":"A42","DOI":"10.1016\/j.vaccine.2020.12.036","volume":"39","author":"F Colrat","year":"2021","unstructured":"Colrat, F., E. Thommes, N. Largeron, and F. P. Alvarez. 2021. Economic evaluation of high-dose inactivated influenza vaccine in adults aged \u226565 years: A systematic literature review. Vaccine 39 (Suppl 1): A42\u2013A50. https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.036.","journal-title":"Vaccine"},{"key":"2000_CR15","doi-asserted-by":"publisher","unstructured":"Coura, A. S., C. A. Nogueira, F. P. Alves, J. S. da Arag\u00e3o, I. S. X. de Fran\u00e7a, K. K. A. S Medeiros. 2015. Quality of life of caregivers of octogenarians: A study using the WHOQOL-BREF. Investig y Educ en Enferm. 33 (3): 529\u2013538. https:\/\/doi.org\/10.17533\/udea.iee.v33n3a17.","DOI":"10.17533\/udea.iee.v33n3a17"},{"issue":"4","key":"2000_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","volume":"15","author":"D Curran","year":"2019","unstructured":"Curran, D., B. J. Patterson, D. Van Oorschot, et al. 2019. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Human Vaccines & Immunotherapeutics 15 (4): 765\u2013771. https:\/\/doi.org\/10.1080\/21645515.2018.1558689.","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"2000_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-018-1213-5","volume":"16","author":"PT de Boer","year":"2018","unstructured":"de Boer, P. T., A. van Lier, H. de Melker, et al. 2018. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: A comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Medicine 16 (1): 228. https:\/\/doi.org\/10.1186\/s12916-018-1213-5.","journal-title":"BMC Medicine"},{"issue":"3","key":"2000_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/07853890.2017.1417632","volume":"50","author":"E de Gomensoro","year":"2018","unstructured":"de Gomensoro, E., G. Del Giudice, and T. M. Doherty. 2018. Challenges in adult vaccination. Annals of Medicine 50 (3): 181\u2013192. https:\/\/doi.org\/10.1080\/07853890.2017.1417632.","journal-title":"Annals of Medicine"},{"issue":"6","key":"2000_CR19","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s12325-021-01717-7","volume":"38","author":"J D\u00edez-Domingo","year":"2021","unstructured":"D\u00edez-Domingo, J., D. Curran, M. D. R. Cambronero, J.-A. Garcia-Martinez, and S. Matthews. 2021. Economic burden and impact on quality of life of herpes zoster in spanish adults aged 50 years or older: A prospective cohort study. Advances in Therapy 38 (6): 3325\u20133341. https:\/\/doi.org\/10.1007\/s12325-021-01717-7.","journal-title":"Advances in Therapy"},{"issue":"3","key":"2000_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s41999-018-0040-8","volume":"9","author":"TM Doherty","year":"2018","unstructured":"Doherty, T. M., M. P. Connolly, G. Del Giudice, et al. 2018. Vaccination programs for older adults in an era of demographic change. European Geriatric Medicine. 9 (3): 289\u2013300. https:\/\/doi.org\/10.1007\/s41999-018-0040-8.","journal-title":"European Geriatric Medicine."},{"issue":"2","key":"2000_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0266462317000526","volume":"33","author":"R Drost","year":"2017","unstructured":"Drost, R., I. M. Van Der Putten, D. Ruwaard, S. M. A. A. Evers, and A. T. G. Paulus. 2017. Conceptualizations of the societal perspective within economic evaluations: A systematic review. International Journal of Technology Assessment in Health Care 33 (2): 251\u2013260. https:\/\/doi.org\/10.1017\/S0266462317000526.","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"0123456789","key":"2000_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s40273-021-01074-x","volume":"39","author":"L Engel","year":"2021","unstructured":"Engel, L., S. Bryan, and D. G. T. Whitehurst. 2021. Conceptualising \u2018benefits beyond health\u2019 in the context of the quality-adjusted life-year: A critical interpretive synthesis. PharmacoEconomics 39 (0123456789): 1383\u20131395. https:\/\/doi.org\/10.1007\/s40273-021-01074-x.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"2000_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/17476348.2019.1555040","volume":"13","author":"C Feldman","year":"2019","unstructured":"Feldman, C., and E. Shaddock. 2019. Epidemiology of lower respiratory tract infections in adults. Expert Review of Respiratory Medicine 13 (1): 63\u201377. https:\/\/doi.org\/10.1080\/17476348.2019.1555040.","journal-title":"Expert Review of Respiratory Medicine"},{"key":"2000_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s43058-022-00280-8","author":"I Francetic","year":"2022","unstructured":"Francetic, I., R. Meacock, J. Elliott, et al. 2022. Framework for identification and measurement of spillover effects in policy implementation: Intended non-intended targeted non-targeted spillovers (INTENTS). Implementation Science Communications. https:\/\/doi.org\/10.1186\/s43058-022-00280-8.","journal-title":"Implementation Science Communications"},{"issue":"2","key":"2000_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/jebm.12525","volume":"16","author":"Y Fu","year":"2023","unstructured":"Fu, Y., J. Zhao, P. Han, et al. 2023. Cost-effectiveness of COVID-19 vaccination: A systematic review. Journal of Evidence-Based Medicine 16 (2): 152\u2013165. https:\/\/doi.org\/10.1111\/jebm.12525.","journal-title":"Journal of Evidence-Based Medicine"},{"key":"2000_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12889-015-1514-y","volume":"15","author":"A Gater","year":"2015","unstructured":"Gater, A., M. Uhart, R. McCool, and E. Pr\u00e9aud. 2015. The humanistic, economic and societal burden of herpes zoster in Europe: A critical review. BMC Public Health 15:193. https:\/\/doi.org\/10.1186\/s12889-015-1514-y.","journal-title":"BMC Public Health"},{"issue":"2","key":"2000_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant, M. J., and A. Booth. 2009. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information and Libraries Journal 26 (2): 91\u2013108. https:\/\/doi.org\/10.1111\/j.1471-1842.2009.00848.x.","journal-title":"Health Information and Libraries Journal"},{"issue":"3","key":"2000_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.vaccine.2022.12.004","volume":"41","author":"J Guo","year":"2023","unstructured":"Guo, J., H. Zhang, H. Zhang, et al. 2023. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study. Vaccine. 41 (3): 716\u2013723. https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.004.","journal-title":"Vaccine."},{"issue":"2","key":"2000_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","volume":"161","author":"M Harvey","year":"2020","unstructured":"Harvey, M., L. A. Prosser, A. M. Rose, I. R. Ortega-Sanchez, and R. Harpaz. 2020. Aggregate health and economic burden of herpes zoster in the United States: Illustrative example of a pain condition. Pain 161 (2): 361\u2013368. https:\/\/doi.org\/10.1097\/j.pain.0000000000001718.","journal-title":"Pain"},{"key":"2000_CR30","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. 2020. Choices in methods for economic evaluation \u2013 HAS. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf."},{"key":"2000_CR31","unstructured":"Health Information and Quality Authority. 2020. Guidelines for the economic evaluation of health technologies in Ireland 2020."},{"issue":"3","key":"2000_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40273-023-01321-3","volume":"42","author":"E Henry","year":"2024","unstructured":"Henry, E., H. Al-Janabi, W. Brouwer, et al. 2024. Recommendations for emerging good practice and future research in relation to family and caregiver health spillovers in health economic evaluations: A report of the SHEER task force. PharmacoEconomics 42 (3): 343\u2013362. https:\/\/doi.org\/10.1007\/s40273-023-01321-3.","journal-title":"PharmacoEconomics"},{"issue":"12","key":"2000_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40273-013-0104-z","volume":"31","author":"RJ Hoefman","year":"2013","unstructured":"Hoefman, R. J., J. Van Exel, and W. Brouwer. 2013. How to include informal care in economic evaluations. PharmacoEconomics 31 (12): 1105\u20131119. https:\/\/doi.org\/10.1007\/s40273-013-0104-z.","journal-title":"PharmacoEconomics"},{"issue":"9","key":"2000_CR34","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14760584.2021.1952869","volume":"20","author":"A Igarashi","year":"2021","unstructured":"Igarashi, A., E. Hirose, Y. Kobayashi, N. Yonemoto, and B. Lee. 2021. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Review of Vaccines 20 (9): 1153\u20131165. https:\/\/doi.org\/10.1080\/14760584.2021.1952869.","journal-title":"Expert Review of Vaccines"},{"issue":"4","key":"2000_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1017\/S0266462320000471","volume":"36","author":"LMM Janssen","year":"2020","unstructured":"Janssen, L. M. M., I. Pokhilenko, S. M. A. A. Evers, et al. 2020. Exploring the identification, validation, and categorization of the cost and benefits of criminal justice in mental health: The PECUNIA project. International Journal of Technology Assessment in Health Care 36 (4): 418\u2013425. https:\/\/doi.org\/10.1017\/S0266462320000471.","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"7","key":"2000_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2131167","volume":"18","author":"D Javier Balan","year":"2022","unstructured":"Javier Balan, D., A. Bardach, C. Palermo, et al. 2022. Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis. Human Vaccines & Immunotherapeutics 18 (7) : 2131167. https:\/\/doi.org\/10.1080\/21645515.2022.2131167.","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"2000_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-015-0446-9","volume":"13","author":"M Jit","year":"2015","unstructured":"Jit, M., R. Hutubessy, M. E. Png, et al. 2015. The broader economic impact of vaccination: Reviewing and appraising the strength of evidence. BMC Medicine 13 (1): 1\u20139. https:\/\/doi.org\/10.1186\/s12916-015-0446-9.","journal-title":"BMC Medicine"},{"issue":"5","key":"2000_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14760584.2019.1588727","volume":"18","author":"W Kandeil","year":"2019","unstructured":"Kandeil, W., P. Atanasov, D. Avramioti, J. Fu, N. Demarteau, and X. Li. 2019. The burden of pertussis in older adults: What is the role of vaccination? A systematic literature review. Expert Review of Vaccines 18 (5): 439\u2013455. https:\/\/doi.org\/10.1080\/14760584.2019.1588727.","journal-title":"Expert Review of Vaccines"},{"issue":"10","key":"2000_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim, D. D., M. C. Silver, N. Kunst, J. T. Cohen, D. A. Ollendorf, and P. J. Neumann. 2020. Perspective and costing in cost-effectiveness analysis, 1974\u20132018. PharmacoEconomics 38 (10): 1135\u20131145. https:\/\/doi.org\/10.1007\/s40273-020-00942-2.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"2000_CR40","doi-asserted-by":"publisher","first-page":"2054602","DOI":"10.1080\/21645515.2022.2054602","volume":"18","author":"I Kolobova","year":"2022","unstructured":"Kolobova, I., M. K. Nyaku, A. Karakusevic, D. Bridge, I. Fotheringham, and M. O\u2019Brien. 2022. Burden of vaccine-preventable diseases among at-risk adult populations in the US. Human Vaccines & Immunotherapeutics 18 (5): 2054602. https:\/\/doi.org\/10.1080\/21645515.2022.2054602.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"2000_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpubeco.2016.11.012","volume":"145","author":"D Lakdawalla","year":"2017","unstructured":"Lakdawalla, D., A. Malani, and J. Reif. 2017. The insurance value of medical innovation. Journal of Public Economics 145:94\u2013102. https:\/\/doi.org\/10.1016\/j.jpubeco.2016.11.012.","journal-title":"Journal of Public Economics"},{"issue":"2","key":"2000_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla, D. N., J. A. Doshi, L. P. Garrison, C. E. Phelps, A. Basu, and P. M. Danzon. 2018. Defining elements of value in health care\u2014a health economics approach: An ISPOR special task force report [3]. Value Heal. 21 (2): 131\u2013139. https:\/\/doi.org\/10.1016\/j.jval.2017.12.007.","journal-title":"Value Heal."},{"issue":"4","key":"2000_CR43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40520-019-01374-5","volume":"33","author":"P-O Lang","year":"2021","unstructured":"Lang, P.-O., and R. Aspinall. 2021. Vaccination for quality of life: Herpes-zoster vaccines. Aging Clinical and Experimental Research 33 (4): 1113\u20131122. https:\/\/doi.org\/10.1007\/s40520-019-01374-5.","journal-title":"Aging Clinical and Experimental Research"},{"key":"2000_CR44","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s10198-023-01658-8","volume":"25","author":"MJ Mendoza-Jim\u00e9nez","year":"2024","unstructured":"Mendoza-Jim\u00e9nez, M. J., J. van Exel, and W. Brouwer. 2024. On spillovers in economic evaluations: Definition, mapping review and research agenda. The European Journal of Health Economics 25:1239\u20131260. https:\/\/doi.org\/10.1007\/s10198-023-01658-8.","journal-title":"The European Journal of Health Economics"},{"key":"2000_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpsychires.2014.03.021","volume":"54","author":"A Millier","year":"2014","unstructured":"Millier, A., U. Schmidt, M. C. Angermeyer, et al. 2014. Humanistic burden in schizophrenia: A literature review. Journal of Psychiatric Research 54:85\u201393. https:\/\/doi.org\/10.1016\/j.jpsychires.2014.03.021.","journal-title":"Journal of Psychiatric Research"},{"key":"2000_CR46","doi-asserted-by":"publisher","unstructured":"Moghadas, S. M., A. Shoukat, C. E. Bawden, et al. 2023. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the US. medRxiv Prepr Serv Heal Sci. https:\/\/doi.org\/10.1101\/2023.08.14.23294076.","DOI":"10.1101\/2023.08.14.23294076"},{"key":"2000_CR47","unstructured":"NACI. 2023. Guidelines for the economic evaluation of vaccination programs in Canada. 1st ed. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/incorporating-economic-evidence-federal-vaccine-recommendations\/guidelines-evaluation-vaccination-programs-canada."},{"key":"2000_CR48","unstructured":"NICE. 2022. NICE health technology evaluations: The manual. https:\/\/www.nice.org.uk\/process\/pmg36."},{"issue":"2","key":"2000_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","volume":"27","author":"AB O\u2019Connor","year":"2009","unstructured":"O\u2019Connor, A. B. 2009. Neuropathic pain: Quality-of-life impact, costs and cost effectiveness of therapy. PharmacoEconomics 27 (2): 95\u2013112. https:\/\/doi.org\/10.2165\/00019053-200927020-00002.","journal-title":"PharmacoEconomics"},{"key":"2000_CR50","unstructured":"Ortega-Sanchez, I. 2025. Economics of respiratory syncytial virus vaccination in adults aged 50\u201359 years at increased risk of severe RSV Disease. In: ACIP Meeting. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/05-Ortega-Sanchez-Adult-RSV-508.pdf."},{"issue":"4","key":"2000_CR51","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1017\/S0266462320000471","volume":"36","author":"I Pokhilenko","year":"2020","unstructured":"Pokhilenko, I., L. M. M. Janssen, S. M. A. A. Evers, et al. 2020. Exploring the identification, validation, and categorization of the cost and benefits of education in mental health: The PECUNIA project. International Journal of Technology Assessment in Health Care 36 (4): 418\u2013425. https:\/\/doi.org\/10.1017\/S0266462320000471.","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"30","key":"2000_CR52","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1016\/j.vaccine.2022.04.026","volume":"40","author":"M Postma","year":"2022","unstructured":"Postma, M., E. Biundo, A. Chicoye, et al. 2022. Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts. Vaccine 40 (30): 3999\u20134007. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.026.","journal-title":"Vaccine"},{"key":"2000_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijid.2017.02.021","volume":"58","author":"E Rampakakis","year":"2017","unstructured":"Rampakakis, E., C. Pollock, C. Vujacich, et al. 2017. Economic burden of herpes zoster (\u201cculebrilla\u201d) in Latin America. International Journal of Infectious Diseases 58:22\u201326. https:\/\/doi.org\/10.1016\/j.ijid.2017.02.021.","journal-title":"International Journal of Infectious Diseases"},{"issue":"10","key":"2000_CR54","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders, G. D., P. J. Neumann, A. Basu, et al. 2016. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA - Journal of the American Medical Association 316 (10): 1093\u20131103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA - Journal of the American Medical Association"},{"issue":"8","key":"2000_CR55","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/gerona\/gly218","volume":"74","author":"KE Schmader","year":"2019","unstructured":"Schmader, K. E., M. J. Levin, K. Grupping, et al. 2019. The impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: An open-label, phase III trial. Journals of Gerontology. Series a, Biological Sciences and Medical Sciences 74 (8): 1217\u20131224. https:\/\/doi.org\/10.1093\/gerona\/gly218.","journal-title":"Journals of Gerontology. Series a, Biological Sciences and Medical Sciences"},{"issue":"33","key":"2000_CR56","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1016\/j.vaccine.2018.06.044","volume":"36","author":"S Sheikh","year":"2018","unstructured":"Sheikh, S., E. Biundo, S. Courcier, et al. 2018. A report on the status of vaccination in Europe. Vaccine. 36 (33): 4979\u20134992. https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.044.","journal-title":"Vaccine."},{"issue":"2","key":"2000_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13555-019-0291-4","volume":"9","author":"M Shiragami","year":"2019","unstructured":"Shiragami, M., A. Mizukami, T. Kaise, et al. 2019. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatology and Therapy 9 (2): 281\u2013297. https:\/\/doi.org\/10.1007\/s13555-019-0291-4.","journal-title":"Dermatology and Therapy"},{"key":"2000_CR58","doi-asserted-by":"publisher","unstructured":"Simoens, S., S. Tubeuf, N. Dauby, et al. 2024. The broader benefits of vaccines: methodologies for inclusion in economic evaluation. Expert Review Vaccines. https:\/\/doi.org\/10.1080\/14760584.2024.2387599.","DOI":"10.1080\/14760584.2024.2387599"},{"issue":"37","key":"2000_CR59","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1016\/j.vaccine.2023.07.025","volume":"41","author":"D Singer","year":"2023","unstructured":"Singer, D., A. Salem, N. Stempniewicz, S. Ma, S. Poston, and D. Curran. 2023. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50\u201359 years. Vaccine. 41 (37): 5360\u20135367. https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.025.","journal-title":"Vaccine."},{"issue":"2","key":"2000_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/14760584.2022.2016399","volume":"21","author":"T Tantawichien","year":"2022","unstructured":"Tantawichien, T., L. Y. Hsu, O. Zaidi, et al. 2022. Systematic literature review of the disease burden and vaccination of pneumococcal disease among adults in select Asia-Pacific areas. Expert Review of Vaccines 21 (2): 215\u2013226. https:\/\/doi.org\/10.1080\/14760584.2022.2016399.","journal-title":"Expert Review of Vaccines"},{"issue":"1","key":"2000_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/13696998.2021.2008195","volume":"25","author":"S Udayachalerm","year":"2022","unstructured":"Udayachalerm, S., M. G. Renouard, T. Anothaisintawee, A. Thakkinstian, S. K. Veettil, and N. Chaiyakunapruk. 2022. Incremental net monetary benefit of herpes zoster vaccination: A systematic review and meta-analysis of cost-effectiveness evidence. Journal of Medical Economics 25 (1): 26\u201337. https:\/\/doi.org\/10.1080\/13696998.2021.2008195.","journal-title":"Journal of Medical Economics"},{"key":"2000_CR62","doi-asserted-by":"publisher","unstructured":"Voormolen, D. C., J. A. M. Bom, E. W. De Bekker-Grob, W. B. F. Brouwer, J. Van Exel. 2024. Development and content validation of the 10-item Well-being Instrument (WiX) for use in economic evaluation studies. Appl Res Qual Life. 1\u201320. https:\/\/doi.org\/10.1007\/s11482-023-10241-5.","DOI":"10.1007\/s11482-023-10241-5"},{"issue":"1","key":"2000_CR63","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1186\/s12889-022-14581-z","volume":"22","author":"NM Waite","year":"2022","unstructured":"Waite, N. M., J. A. Pereira, S. K. D. Houle, V. Gilca, and M. K. Andrew. 2022. The impact of influenza on the ability to work, volunteer and provide care: Results from an online survey of Canadian adults 50 years and older. BMC Public Health 22 (1): 2119. https:\/\/doi.org\/10.1186\/s12889-022-14581-z.","journal-title":"BMC Public Health"},{"key":"2000_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/1753466621995050","author":"A Watson","year":"2021","unstructured":"Watson, A., and T. M. A. Wilkinson. 2021. Respiratory viral infections in the elderly. Therapeutic Advances in Respiratory Disease. https:\/\/doi.org\/10.1177\/1753466621995050.","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"2000_CR65","unstructured":"WHO. 2020. Immunization Agenda 2030: A Global Strategy To Leave No One Behind. https:\/\/www.who.int\/publications\/m\/item\/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind."},{"issue":"9","key":"2000_CR66","doi-asserted-by":"publisher","first-page":"e13188","DOI":"10.1111\/irv.13188","volume":"17","author":"T Wilkinson","year":"2023","unstructured":"Wilkinson, T., S. Beaver, M. Macartney, E. McArthur, V. Yadav, and A. Lied-Lied. 2023. Burden of respiratory syncytial virus in adults in the United Kingdom: A systematic literature review and gap analysis. Influenza and Other Respiratory Viruses 17 (9): e13188. https:\/\/doi.org\/10.1111\/irv.13188.","journal-title":"Influenza and Other Respiratory Viruses"},{"issue":"5","key":"2000_CR67","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00520-018-4419-3","volume":"27","author":"R Wood","year":"2019","unstructured":"Wood, R., G. Taylor-Stokes, and M. Lees. 2019. The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries\u2014a real-world survey of caregivers. Supportive Care in Cancer 27 (5): 1709\u20131719. https:\/\/doi.org\/10.1007\/s00520-018-4419-3.","journal-title":"Supportive Care in Cancer"},{"key":"2000_CR68","unstructured":"World Health Organization. 2019. WHO guide on standardization of economic evaluations of immunization programmes. https:\/\/www.who.int\/immunization\/documents\/who_ivb_19.10\/en\/."},{"key":"2000_CR69","unstructured":"ZIN. 2016. Guideline for economic evaluations in healthcare. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-02000-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-02000-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-02000-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:02:05Z","timestamp":1792789325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-02000-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":69,"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-02000-8","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}